The TARGET Study

The TARGET Study will test whether 90 day survival and functional outcomes following critical illness may be improved by increased calorie delivery.

The TARGET Study

Background

  • Nutrition therapy is an essential standard of care for all ICU patients who are mechanically ventilated and remain in ICU for more than a few days
  • Enteral nutrition (via a nasogastric tube) is usually initiated within 24 hours of ICU admission
  • Previous trials support the concept that optimising nutrition in the critically ill will improve outcome, however, the evidence is limited, inconclusive and generally of low quality

Facts

  • Each year around 130,000 Australians are admitted to ICU at a daily cost of approximately $4000 per patient
  • Critically ill patients require substantial resources and multiple interventions, some die and many of those who survive have delayed and compromised functional recovery which can persist for months or years

Aims

Primary: to determine if augmentation of calorie delivery using energy dense enteral nutrition in mechanically ventilated patients improves 90 day survival when compared to routine care.

Secondary: to determine if augmentation of calorie delivery using energy dense enteral nutrition in mechanically ventilated patients improves functional outcomes when compared to routine care.

Methods

  • A 4000 patient, multi-centre, double-blinded, randomised, controlled, parallel-group, phase III clinical trial.
  • Eligible patients will be randomised 1:1 to receive TARGET protocol enteral nutrition formulation of either 1 kcal/ml or 1.5 kcal/ml
  • TARGET will be conducted in ICUs in Australia and New Zealand

Supported by:  National Health and medical Research Council (NHMRC), Australia & Fresenius Kabi Deutschland GmbH

Coordinating centre: The ANZIC-RC, School of Public Health and Preventative Medicine, Monash University

Chief Investigator: Professor Marianne Chapman, Director of Research / Senior Staff Specialist Intensive Care Unit, Royal Adelaide Hospital

Contact: Lorraine Little, Senior Project Manager,ANZIC-RC, School of Public Health and Preventative Medicine, Monash University

Software: Spinnaker, Spiral Software

Download the TARGET Fact Sheet (pdf)

Twitter

Read what people are saying about the TARGET Trial on Twitter

#TARGETtrial

Read what people are saying about the TARGET Trial on Twitter.
#TARGETtrial

Study Database

Sign in to the study (username + password needed)

Study Database

The TARGET Trial is open and enrolling patients. If you have a username and password you can sign in from here.
Study Database

ANZCTR

View this trial on the Australian and New Zealand Clinical Trial Registry

ANZCTR

View this trial on the Australian and New Zealand Clinical Trial Registry. 
ACTRN12611000793910